Agenda for October 2024 Cancer Treatments Advisory Committee meeting
Information on what the Cancer Treatments Advisory Committee will be considering at its upcoming meeting in October 2024.
Matters arising and correspondence
Nivolumab and ipilimumab for melanoma that has spread or can’t be removed by surgery
The Committee will discuss feedback we received following consultation on Pharmac’s proposal to decline funding for this treatment. The feedback indicated that there is more recent information around the use of these medicines. The Committee will discuss if this new information changes their assessment of how beneficial these medicines are in melanoma.
Application for Nivolumab and ipilimumab | Application Tracker(external link)
Record of PTAC meeting May 2016 [PDF, 87 KB]
Decision to decline inactive funding applications
Applications
Bevacizumab with lomustine for a type of brain tumour
The Committee will advise us on the use of bevacizumab in combination with lomustine for people with relapsed or recurrent high-grade glioma (a type of fast-growing brain tumour). The Committee has reviewed this application before and has also reviewed bevacizumab monotherapy for relapsed or recurrent glioma (at a time when the supplier of lomustine expected that treatment to become unavailable).
The Committee will give us updated advice on the evidence for the combination of bevacizumab and lomustine for glioma and how this combination might be used in New Zealand, if funded.
Application for bevacizumab in combination with lomustine for the treatment of glioma(external link)
Application for bevacizumab monotherapy for the treatment of glioma(external link)
Record of PTAC meeting February 2016 [PDF, 847 KB]
Bevacizumab for colorectal cancer
The Committee will give us updated advice on the use of bevacizumab for people with metastatic colorectal cancer whose disease has only spread to the liver (“liver-only metastases”). The Committee has reviewed this application before, most recently in 2014. We are seeking updated advice because the evidence and treatment for colorectal cancer with liver-only metastases has changed since it was last reviewed.
Application for bevacizumab for colorectal cancer with liver-only metastases(external link)
Record of PTAC meeting August 2014 [PDF, 240 KB]
BRAF/MEK inhibitors for melanoma
The Committee will advise us on the use of BRAF/MEK inhibitors such as dabrafenib and trametinib for people with melanoma receiving treatment after surgery (adjuvant treatment). The Committee will also advise us on the use of adjuvant treatments and how these might affect other treatments if the cancer spreads to other areas of the body (metastatic).
Pegylated liposomal doxorubicin for ovarian cancer
The Committee will advise us on the use of a particular preparation of doxorubicin (pegylated liposomal doxorubicin) for people with advanced ovarian cancer. The Committee has reviewed this application before and will advise us on the updated evidence.
Record of PTAC meeting February 2012 [PDF, 169 KB]
Renal cell carcinoma treatment paradigm
The Committee will discuss treatments for renal cell carcinoma. We seek the Committee’s advice on the relative health benefit of different treatments, and how treatments would be used if one or multiple new medicines were to be funded.
Asciminib for Chronic myeloid leukaemia, previously treated with two or more tyrosine kinase inhibitors (P-002030)
The Committee will provide initial advice on a new application for the use of asciminib for the treatment of a type of blood cancer (Philadelphia chromosome-positive chronic myeloid leukaemia [Ph+ CML] in the chronic phase), after two or more treatments have already been tried (third line, and fourth-line treatment).
Application for asciminib for CML(external link)
Blinatumomab for minimal residual disease in B cell lineage acute lymphoblastic leukaemia (P-002022)
The Committee will provide initial advice on a new application for blinatumomab for the treatment of a type of blood cancer (B cell lineage acute lymphoblastic leukaemia [ALL]), for people who have minimal residual disease following induction chemotherapy.
Ruxolitinib for a condition that occurs after a stem cell (bone marrow) transplant
The Committee will advise us on the use of ruxolitinib for people with acute graft versus host disease (GvHD) following allogenic hematopoietic stem cell transplant (HSCT), who have received prior treatment with corticosteroids. This follows advice we sought from CTAC in July 2024 about ruxolitinib for the treatment of chronic GvHD.
Application for ruxolitinib for acute GvGD following HSCT(external link)
Application for ruxolitinib for chronic GvGD following HSCT(external link)